Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system
{{output}}
The United States Food and Drug Administration (FDA) has been warning about the psychiatric disorders associated with montelukast (MTK) for years. To study the characteristics of the presence of MTK-associated adverse events (AEs), we obtained data from the FD... ...
